All In Biotech

Free tool

FAERS Monitor: Asclera

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021201 or its brand name (Asclera, Polidocanol). Reports on generic versions are filed under their own applications.

Reports

450

Serious

263

58% of reports

Hospitalization

114

Death reported

15

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • deep vein thrombosis35
  • pain28
  • pruritus28
  • off label use27
  • erythema26
  • dizziness24
  • swelling24
  • injection site pain23
  • pain in extremity23
  • nausea22
  • urticaria22
  • drug ineffective20
  • skin discolouration19
  • pulmonary embolism18
  • hypersensitivity17

Reports by year received

View as table
YearReports
20071
20081
20092
20114
20126
201321
20146
201519
201634
201748
201864
201928
202043
202127
202246
202319
202418
202524
202639

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,709 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
deep vein thrombosisSignal3525.218.3791
skin discolourationSignal1919.312.4313
swellingSignal2412.08.1232
pulmonary embolismSignal188.95.6118
urticariaSignal226.14.190
erythemaSignal265.94.1102
hypersensitivitySignal174.32.740
pain in extremitySignal233.62.542
injection site painSignal233.52.439
pruritusSignal283.42.446
dizzinessSignal242.21.516
painSignal282.11.516
off label use271.41.03
nausea221.30.91
drug ineffective200.70.52

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.